Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition

Cell Death Discovery
Almuth F KesslerCarsten Hagemann

Abstract

Tumor treating fields (TTFields) are approved for glioblastoma (GBM) therapy. TTFields disrupt cell division by inhibiting spindle fiber formation. Spindle assembly checkpoint (SAC) inhibition combined with antimitotic drugs synergistically decreases glioma cell growth in cell culture and mice. We hypothesized that SAC inhibition will increase TTFields efficacy. Human GBM cells (U-87 MG, GaMG) were treated with TTFields (200 kHz, 1.7 V/cm) and/or the SAC inhibitor MPS1-IN-3 (IN-3, 4 µM). Cells were counted after 24, 48, and 72 h of treatment and at 24 and 72 h after end of treatment (EOT). Flow cytometry, immunofluorescence microscopy, Annexin-V staining and TUNEL assay were used to detect alterations in cell cycle and apoptosis after 72 h of treatment. The TTFields/IN-3 combination decreased cell proliferation after 72 h compared to either treatment alone (-78.6% vs. TTFields, P = 0.0337; -52.6% vs. IN-3, P = 0.0205), and reduced the number of viable cells (62% less than seeded). There was a significant cell cycle shift from G1 to G2/M phase (P < 0.0001). The apoptotic rate increased to 44% (TTFields 14%, P = 0.0002; IN-3 4%, P < 0.0001). Cell growth recovered 24 h after EOT with TTFields and IN-3 alone, but the combination le...Continue Reading

References

May 6, 2004·Cancer Research·Eilon D KirsonYoram Palti
Aug 19, 2004·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Guido Reifenberger, Vincent Peter Collins
Jun 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Eilon D KirsonYoram Palti
Oct 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Aniek JanssenRené H Medema
May 5, 2011·Molecular Interventions·Daniel R Matson, P Todd Stukenberg
Jan 10, 2012·Cell Death and Differentiation·E ManchadoM Malumbres
May 29, 2012·Bioorganic & Medicinal Chemistry Letters·D Vijay KumarRobert O Carlson
Aug 30, 2012·Nature Methods·Caroline A SchneiderKevin W Eliceiri
Aug 13, 2013·Cell Death and Differentiation·M JemaàG Kroemer
Aug 14, 2013·Journal of the National Cancer Institute·Bakhos A TannousThomas Würdinger
Jul 15, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A R R MaiaR H Medema
Nov 23, 2015·Molecular Cell·Carmen Dominguez-BrauerTak W Mak
Dec 17, 2015·JAMA : the Journal of the American Medical Association·Roger StuppZvi Ram
Feb 3, 2016·Molecular Cancer Therapeutics·Antje M WengnerKarl Ziegelbauer
May 24, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yuji Nakayama, Toshiaki Inoue
Feb 9, 2017·Pharmacology & Therapeutics·Larissa Siqueira PennaDiego Bonatto
Mar 6, 2017·Bioorganic & Medicinal Chemistry·Yasuro SugimotoRobert W Brueggemeier
Mar 9, 2017·Proceedings of the National Academy of Sciences of the United States of America·Jacqueline M MasonTak W Mak
Apr 21, 2017·Cell Death & Disease·Manuela SilginerPatrick Roth
May 19, 2017·Journal of Visualized Experiments : JoVE·Yaara PoratYoram Palti
Jul 5, 2017·Methods in Molecular Biology·Carsten HagemannMario Löhr
Jul 8, 2017·Endocrine-related Cancer·Bing Cheng, Karen Crasta
Aug 30, 2017·Journal of Neuro-oncology·Rimas V LukasJohn L Villano

❮ Previous
Next ❯

Citations

Dec 20, 2018·Oncotarget·Joshua BranterStuart Smith
Nov 25, 2018·International Journal of Molecular Sciences·Yunhui JoMyonggeun Yoon
Feb 13, 2021·AAPS PharmSciTech·Kanawat WiwatchaitaweeAliasger K Salem
Nov 5, 2020·British Journal of Cancer·Ola RominiyiSpencer James Collis
Jun 3, 2021·Cancers·Alondra A AguilarChirag B Patel
Dec 10, 2021·Expert Review of Molecular Diagnostics·Pengjie HongDongxiao Zhuang

❮ Previous
Next ❯

Methods Mentioned

BETA
phase contrast microscopy
FACS
flow cytometry
Assay

Software Mentioned

LAS
GraphPad
TTFields
GraphPad Prism
Flowing
ImageJ

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis